Effectiveness and safety of cladribine in MS: Insights from a retrospective single-center study

Key Points

• Cladribine demonstrated promising effectiveness in treating multiple sclerosis, particularly in reducing relapse rates.
• Observational analysis revealed a notable decrease in relapse rates by 32% among patients treated with cladribine.
• The retrospective study examined data from a single center over several years to evaluate treatment safety and outcomes.
• These findings highlight cladribine's potential role in clinical practice for managing multiple sclerosis.